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BackgroundandAims.This study examined if exercise and omega-3 fatty acid (n3PUFA) supplementation is an eﬀective treatment
for hepatic steatosis in obese, hyperphagic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Methods. Male OLETF rats were
divided into 4 groups (n = 8/group): (1) remained sedentary (SED), (2) access to running wheels; (EX) (3) a diet supplemented
with 3% of energy from ﬁsh oil (n3PUFA-SED); and (4) n3PUFA supplementation plus EX (n3PUFA+EX). The 8 week treatments
beganat13weeks,whenhepaticsteatosisispresentinOLETF-SEDrats.Results. EXaloneloweredhepatictriglyceride(TAG)while,
in contrast, n3PUFAs failed to lower hepatic TAG and blunted the ability of EX to decrease hepatic TAG levels in n3PUFAs+EX.
Insulin sensitivity was improved in EX animals, to a lesser extent in n3PUFA+EX rats, and did not diﬀer between n3PUFA-SED
and SED rats. Only the EX group displayed higher complete hepatic fatty acid oxidation (FAO) to CO2 and carnitine palmitoyl
transferase-1 activity. EX also lowered hepatic fatty acid synthase protein while both EX and n3PUFA+EX decreased stearoyl CoA
desaturase-1 protein. Conclusions. Exercise lowers hepatic steatosis through increased complete hepatic FAO, insulin sensitivity,
and reduced expression of de novo fatty acid synthesis proteins while n3PUFAs had no eﬀect.
1.Introduction
It is estimated that 20–40% of the general population
and 50–90% of obese people have nonalcoholic fatty liver
disease (NAFLD) [1, 2]. The presence of NAFLD has been
described as an independent risk factor for the development
of cardiovascular disease [3–5], and it often accompanies
other obesity-related diseases such as type 2 diabetes and
is considered the hepatic manifestation of the metabolic
syndrome [6]. Further, NAFLD is associated with increases
in all-cause and liver-related mortality [7, 8]. As a result,
the examination of aﬀordable treatment options for NAFLD,
such as exercise or omega-3 polyunsaturated fatty acid
(n3PUFA) supplementation, is becoming more imperative.
Unfortunately,thereis apaucity ofstudiesinvestigating exer-
cise and exercise combined with n3PUFA supplementation
as treatments for NAFLD. Most exercise research has been
focused on prevention, and not on treatment or reversal of
preexisting NAFLD.2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
We have previously used the Otsuka Long-Evans
Tokushima Fatty (OLETF) rats to investigate NAFLD
because they spontaneously develop obesity, insulin resis-
tance,andNAFLDwhichprogressivelyworsenswithadvanc-
ing age [9, 10]. OLETF rats lack the cholecystokinin-1
receptor resulting in hyperphagia due to defective satiety
signaling [11]. Further, a novelty of this particular model
is their intrinsic aptitude for exercise (EX) on voluntary
running wheels, a characteristic that is uncommon in obese
rodent models. We have previously shown that EX on
voluntary wheel running beginning at 4 weeks of age in
OLETF rats prevents the development of hepatic steatosis,
eﬀects that were associated with prevention of insulin
resistance and increased hepatic fatty acid oxidation (FAO)
[9]. Moreover, we have established that locking of the wheels
and ceasing daily EX in OLETF rats quickly activate a
subgroup of precursors and processes known to initiate
hepatic steatosis, including decreased hepatic mitochondrial
oxidative capacity, increased hepatic expression of de novo
lipogenesis proteins, and increased hepatic malonyl CoA
levels [12]. Other labs have also shown that exercise can
prevent fatty liver in rodents fed a high-fat-diet to induce
obesity [13, 14]. Although we and others have established
that daily exercise is an invaluable intervention to prevent
NAFLD, it remains unknown if exercise is an eﬀective
treatment strategy for preexisting NAFLD.
Dietary polyunsaturated fatty acids (n3PUFAs) have
also been studied as a treatment for NAFLD. n3PUFAs
both activate a transcription factor that is important for
hepaticoxidativecapacity(peroxisomeproliferator-activated
receptor (PPARα)) and inactivates a master regulator of
hepatic lipid synthesis (sterol regulatory element binding
protein (SREBP)-1c) in rodents [15–22] and humans [23,
24]. This dual action on hepatic metabolism suggests that
n3PUFAs could lower hepatic fat content. In OLETF rats,
dietary intake of n3PUFAs beginning at 5 weeks of age
prevented hepatic steatosis by decreasing the activity of
lipogenic enzymes such as fatty acid synthase (FAS) and
stearoyl CoA desaturase (SCD)-1 and decreasing mRNA
expression of several key lipogenic genes including SREBP-
1c and acetyl CoA carboxylase (ACC) [25]. The authors
also found that mRNA expression and activity of CPT, a
protein that is controlled by PPARα, were increased in the
liver of n3PUFA-fed OLETFs [25]. These results indicate
that n3PUFAs were eﬀective at preventing increased liver
TAG accumulation in OLETF rats; however, this study also
addressed prevention and not treatment of NAFLD.
Treatment of NAFLD with n3PUFAs has also been
examined previously. Seven days of dietary consumption of
n3PUFAs led to reductions, but not complete reversal, of
hepatic steatosis, and systemic insulin resistance in ob/ob
mice,associatedwiththedown-regulationofSREBP-1c[19].
TheauthorsalsoobservedincreasedactivationofPPARαand
its associated gene targets suggesting increased β-oxidation
in the liver, but lacked a quantitative measure of FAO. In
another study, dietary intake of n3PUFAs attenuated, but
was again not able to completely reverse, liver TAG content
following high-fat-diet-induced hepatic steatosis [20].
To our knowledge, we are unaware of any studies that
have examined the individual and combined eﬀects of exer-
ciseandn3PUFAsupplementationonhepaticmitochondrial
FAO and treatment of NAFLD. Thus, the purpose of this
study was to examine the individual and combined eﬀects
of exercise and the dietary intake of omega-3 fatty acids
(3% of energy from ﬁsh oil) to treat preexisting hepatic
steatosis in OLETF rats. We also examined the eﬀects of
these treatments on factors known to play a role in the
developmentofhepaticsteatosisincludingperipheralinsulin
sensitivity, hepatic FAO, and markers of hepatic lipogenesis.
We hypothesized that both exercise and n3PUFAs would
reverse or attenuate progression of NAFLD in obese rats
and that the combination of treatments would have an even
greater eﬀect on treating NAFLD.
2. Methods
2.1. Study Design. The animal protocol was approved by the
Institutional Animal Care and Use Committee at the Univer-
sity of Missouri. Male OLETF rats were generously provided
by the Tokushima Research Institute, Otsuka Pharmaceutical
(Tokushima, Japan) and arrived at 4 weeks of age. Rats
were given ad libitum access to normal chow food (Purina
Formulab Diet, 5008) and water in a temperature- and light-
controlled room (12h light-12h dark cycle). At 13 weeks
of age, an age when obesity, insulin resistance, and NAFLD
are present in sedentary OLETF rats [10], OLETFs were
randomlydivided into4groups(n = 8/group):(1)remained
sedentary (SED) on normal chow, (2) was provided access to
voluntary running wheels (EX) with normal chow, (3) was
provided diet supplemented with 3% of energy from ﬁsh
oil (n3PUFA-SED), and (4) had access to running wheels
and diet supplemented with 3% of energy from ﬁsh oil
(n3PUFA+EX). Thus, treatments began at 13 weeks of age
and ended at 20 weeks of age when rats were euthanized.
Food consumption and body weights were assessed weekly,
and running distances (wheels outﬁtted with a Sigma Sport
BC 800 bicycle computer (Cherry Creek Cyclery, Foster Falls,
VA, USA) for measuring daily running activity) in EX and
n3PUFA-EX rats were measured daily following the end of
the dark cycle during the 8-week treatment period. After
being fasted and having wheels locked for a 5h period, rats
were anesthetized with sodium pentobarbital (100mg/kg),
tissue and blood were collected, fat pads were weighed, and
rats were euthanized by exsanguination.
2.2. Diet. The normal chow diet used was Formulab 5008
(Purina Mills, St. Louis, Mo, USA) which we have used
in previous studies in which the OLETF rats develop
steatosis [9, 10]. The n3PUFA diet was custom-formulated
at the University of Missouri using an AIN-93G diet
supplemented with 3% of energy from menhaden ﬁsh oil.
The menhaden ﬁsh oil was kindly donated by Omega
Protein, Inc. (Houston, Tex, USA) and was stabilized with a
synthetic antioxidant (0.2g/kg tertiary butyl-hydroquinone
(TBHQ)) and 1000mg/kg mixed tocopherols to protect it
from autooxidation. The percent of energy provided by fatJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
was the same between the Formulab 5008 and n3PUFA diet,
16.7%, respectively.
2.3. Intraperitoneal Glucose Tolerance Tests. Baseline glucose
values were determined following a 12h overnight fast one
week prior to sacriﬁce (19 weeks of age). Glucose (2.0g/kg)
wasthenadministeredintraperitoneally,andtailblooddraws
were taken prior to and 15, 30, 45, 60, and 120min following
the bolus of glucose as performed previously by our group
[26].
2.4. Dual-Energy X-Ray Absorptiometry (DEXA). Whole
body composition was determined using a Hologic QDR-
1000/w DEXA machine calibrated for rats as performed
previously by our group [27].
2.5. Serum Measures. The concentrations of glucose (Sigma
Aldrich, St. Louis, Mo, USA), insulin (Millipore, Biller-
ica, Mass, USA), β-hydroxybutyrate (Stanbio Laboratory,
Boerne, Tex, USA), triglycerides (Sigma Aldrich), and free
fatty acids (Wako, Richmond, Va, USA) in plasma were
measured using commercially available kits.
2.6. Liver Tissue Procedures. Livers were quickly excised
from anesthetized rats and were either immediately freeze-
clamped in liquid nitrogen, placed in 10% formalin, or
placed in ice-cold isolation buﬀer and then homogenized as
previously described [9].
2.7. Fatty Acid Oxidation. Fresh tissue fatty acid oxidation
(FAO) using radiolabeled 14C palmitate (Perkin Elmer,
Boston, Mass, USA) was performed as previously described
[27]. Brieﬂy, both 14CO2, representing complete fatty acid
oxidation, and 14C-labeled acid soluble metabolites (14C
ASM), representing incomplete fatty acid oxidation, were
collected in the previously described trapping device and
then counted on a liquid scintillation counter. In addition
to the 14C palmitate, the reaction buﬀer contained a ﬁnal
concentration of 50μM cold palmitate and 0.5% bovine
serum albumin.
2.8. Enzyme Assays. Carnitine palmitoyl transferase-1 (CPT-
1) activity, β-hydroxy-acyl-CoA dehydrogenase activity (β-
HAD), and citrate synthase activity assays were performed as
described previously by our group [27].
2.9. Hepatic Nuclear Isolation. Nuclear extraction of fresh
liver tissue was performed using a commercially available kit
(Marligen Biosciences, Ijamsville, Md, USA). Brieﬂy, fresh
tissue was immediately placed into hypotonic lysis buﬀer,
homogenized, washed, vortexed, and centrifuged. Super-
natant containing the cytoplasmic extracts was removed.
Each sample was washed by centrifugation until the super-
natant was clear. Samples were incubated on ice followed
by a 30min high-speed centrifugation at 4◦C. Supernatant
was removed representing the nuclear extract and stored at
−80◦C.
2.10. Hepatic TAG and DAG Analysis. Hepatic fatty acids
were extracted using a modiﬁed Folch method [28]. Brieﬂy,
livertissuewashomogenizedinice-coldTrizma/EDTAbuﬀer
andlipidswereextractedinchloroform/methanol/aceticacid
(2:1:0.15). Extracted lipids were then run on a thin-layer
chromatography (TLC) silica plate in a tank containing
hexane, diethyl ether, and acetic acid (70:30:1). Triglyceride
and diacylglycerol fractions were scraped from the TLC
plate and were then methylated by incubating with toluene,
methanol, and acetyl chloride (0.5:1.2:0.1) at 100◦Cf o r
60min and separated in hexane. Fatty acid methyl esters
were analyzed by gas chromatography (Agilent Technologies,
Wilmington, De, USA).
2.11.LiverHistology. Hematoxylinandeosin(H&E)staining
wasperformedonformalin-ﬁxedparaﬃn-embeddedsection
of liver as described previously to assess lipid vacuolization
[29].
2.12. Western Blotting. Western blots were performed to
detect protein levels of PPARα (Santa Cruz Biotechnology,
Santa Cruz, Calif, USA), PPARδ (Thermo Scientiﬁc, Rock-
ford, Il, USA), PPARγ (Cell Signaling, Beverly, CA), SREBP-
1c (Santa Cruz Biotechnology), fatty acid synthase (FAS)
(Cell Signaling), acetyl coenzyme A carboxylase (ACC) (Cell
Signaling), and stearoyl CoA desaturase (SCD)-1 (Alpha
Diagnostic International, San Antonio, Tex, USA) as per-
formed previously [9]. Liver samples were homogenized in
ice-cold lysis buﬀer, separated by SDS-PAGE gels, transferred
to PVDF membranes, and probed with primary antibodies.
Proteinbandswerequantiﬁedusingadensitometerandband
densities were corrected for total protein loaded by staining
with 0.1% amido black (Sigma) as described previously [9].
2.13. Gene Expression. Quantitative RT-PCR was performed
as previously described for mRNA expression of PPARα and
PPARδ [26]. Brieﬂy, on the day of sacriﬁce, fresh tissue
was collected and placed in RNAlater (Ambion, Austin,
Tex, USA) stored at 4◦Cf o r2 4 ha n dt h e ns t o r e da t
−20◦C. Liver samples were pulverized in RLT buﬀer using
the QIAGEN TissueLyser system (Valencia, Calif, USA).
RNA was then isolated using a commercially available kit
(QIAGEN, Valencia, Calif, USA). Reverse transcription and
cDNA synthesis were performed according to the manufac-
turer instructions (Promega, Madison, Wis, USA). TaqMan
Master Mix (Applied Biosystems, Foster City, Calif, USA)
for gene targets PPARα and PPARδ were loaded into a 96-
well microplate along with the cDNA sample (5μg/μL) and
placed into the ABI 7000 Sequence Detection System for
polymerization. Results were quantiﬁed relative to β-actin.
Critical threshold (Ct) values for the housekeeping gene did
not diﬀer among groups (data not shown).
2.14. Statistical Analysis. Treatment diﬀerences were ana-
lyzed by one-way analysis of variance (ANOVA) with main
eﬀect signiﬁcance set at P<0.05. Signiﬁcant main eﬀects
were then followed up by least signiﬁcant diﬀerence (LSD)
post hoc comparisons (SPSS 17.0). Data are presented as
means ± SE, and signiﬁcance was set at P<0.05.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Animal and serum characteristics.
SED EX n3PUFA-SED n3PUFA+EX
Final body weight (g) 617.1 ±20.0a 462.0 ±10.5b 571.6 ±10.3c 512.1 ±17.5d
Body fat (%) 31.9 ±0.9a 11.3 ±1.6b 29.5 ±1.1a 18.8 ±1.3c
Fat pad mass (g) 33.1 ±2.0a 9.2 ±1.6b 26.4 ±1.7c 16.4 ±1.8d
Food intake (g) 228.2 ±7.5a 192.2 ±4.0b 226.6 ±5.8a 178.5 ±3.2b
Food wt (g)/BW (g) 0.40 ±0.00a 0.45 ±0.01b 0.40 ±0.00a 0.39 ±0.01a
Caloric intake (kcal) 947.0 ±31.0a 797.8 ±16.7b 853.2 ±21.9b 672.1 ±11.9c
Calories (kcal)/BW (g) 1.67 ±0.01a 1.84 ±0.05b 1.52 ±0.02c 1.48 ±0.03c
Triglycerides (mg/dL) 123.7 ±17.6a 62.1 ±9.4b 59.4 ±5.4b 36.9 ±4.6b
Free fatty acids (μmol/L) 422.6 ±38.4a 199.3 ±25.8b 263.0 ±25.3b 193.4 ±26.5b
Glucose (mg/dL) 396.0 ±14.1a 255.9 ±16.0b 311.9 ±45.1b 239.2 ±14.5b
Insulin (ng/mL) 15.0 ±1.9a 10.0 ±1.3b 11.8 ±1.6a,b 7.6 ±0.9b
H e a r tw t / b o d yw t( m g / g ) 2 .5 ±0.10a 3.5 ±0.01b 2.7 ±0.10a 3.1 ±0.10b
Values are means ± SE (n = 8). Values with diﬀerent letter superscripts are signiﬁcantly diﬀerent from each other (P<0.05). Fat pad mass: omental +
retroperitoneal fat pads; BW: body weight.
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Figure 1:Runningdistanceandbodyweights.Weeklyrundistance(a)duringthe8weektreatmentinterventionandweeklybodyweight(b).
Values are means ± SE (n = 8). ∗EX and n3PUFA+EX are signiﬁcantly diﬀerent from SED and n3PUFA-SED (P<0.05). #EX is signiﬁcantly
diﬀerent from all groups, and n3PUFA+EX is signiﬁcantly diﬀerent than SED and n3PUFA-SED.
3. Results
3.1. Animal and Serum Characteristics. Final body weight
and fat pad mass (omental + retroperitoneal) were sig-
niﬁcantly diﬀerent among all groups (Table 1). Body fat
percentage was highest in the SED and n3PUFA-SED rats;
EX rats had the lowest body fat percentage, over 2.5fold
lower than SED and n3PUFA-SED and 1.6fold lower than
n3PUFA+EX. Fat pad mass mirrored the body fat percentage
measures except that n3PUFA-SED was lower than SED.
Weekly food intake (grams) was reduced in the EX and
n3PUFA+EX groups as compared to SED and n3PUFA-SED.
However, when weekly food intake (grams) was normalized
to body weight, the EX group consumed more than the
SED,n3PUFA-SED,andn3PUFA+EXgroups.Weeklycaloric
intake per body weight was also highest in the EX compared
to all other groups. In addition, the SED group consumed
moreKcalperbodyweightthanthetwogroupswhoreceived
n3PUFA supplementation. All 3 treatment conditions sig-
niﬁcantly lowered circulating TAG and FFAs compared with
SED rats.
3.2. Weekly Run Distance and Body Weight. EX and
n3PUFA+EX rats were given access to running wheels at
13 weeks of age. There were no diﬀerences in weekly
run distances between the two groups (Figure 1(a)). Peak
running distances in both groups were approximately 56 and
55km per week (approximately 8km per night) at 16 weeks
and slowly declined to about 34 and 33km per week (∼5km
per night) by 20 weeks of age. As shown in Figure 1(b),E X
and n3PUFA+EX rats showed a decline in body weight the
ﬁrst two weeks following introduction to wheel running and
then began gaining weight again while SED and n3PUFA-
SED rats continued to gain weight during the 8 weeks of
treatment.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 2: Hepatic fat storage. Fat accumulation in the liver as shown by liver triglyceride content (a), liver diacylglycerol content (b), liver
n3PUFAcontent(EPA+DHA)(c),andrepresentativeimagesofhematoxylinandeosinstainingforlipidvacuolization(d).Valuesaremeans
± SE (n = 8). Values with diﬀerent letter superscripts are signiﬁcantly diﬀerent from each other (P<0.05).
3.3. Hepatic Steatosis. Hepatic TAG content from previously
studied 13-week-old OLETF-SED rats (n = 8) was used
as a baseline measure of hepatic steatosis allowing us to
determine if the 8-week treatments could reverse steatosis.
As shown in Figure 2(a), EX rats had lower TAG content
at 20 weeks of age as compared to the baseline TAG
content of SED-12 wk rats (P = 0.03), indicating EX
eﬀectively treated NAFLD. Although the beneﬁcial eﬀects
of EX were partially blunted in the n3PUFA+EX animals,
liver TAG content was signiﬁcantly lower than SED-20 wk
(P = 0.001). Unexpectedly, n3PUFA supplementation in
sedentary, hyperphagic rats exacerbated hepatic steatosis
a b o v et h a tm e a s u r e di nb o t hS E Dg r o u p s( P<0.05;
Figure 2). Hepatic DAG content (Figure 2(b)) followed sim-
ilar trends as TAG content, with EX and n3PUFA+EX both
oﬀering protection against the accumulation of DAGs in the
liver as compared to SED and n3PUFA-SED. The n3PUFA
content eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) were measured in the liver and showed that EPA
and DHA were incorporated into the liver at a higher level
in n3PUFA-fed rats with n3PUFA-SED having the highest
content(Figure 2(c)).RepresentativeimagesofH&Estaining6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
for lipid vacuolization (Figure 2(c)) demonstrate a visual
presence of steatosis in n3PUFA-SED and SED rats as shown
by the large size and number of lipid droplets, whereas EX
and n3PUFA+EX displayed noticeably less lipid droplets.
3.4. Systemic Insulin Sensitivity. Blood glucose and insulin
lev elsw e r eelevat edinSEDratsasc o mpar edt oEX,n3PUF A -
SED, and n3PUFA+EX (Table 1). Glucose responses to the
tolerance test are shown in Figure 3(a). Glucose and insulin
AUCs during the IPGTT did not diﬀer between n3PUFA and
SED groups, whereas EX rats had signiﬁcantly lower glucose
and insulin AUCs (P<0.01), and n3PUFA-EX rats only had
lower insulin AUCs (P<0.05) as shown in Figures 3(b) and
3(c).
3.5. Hepatic Mitochondrial Function and Fatty Acid Oxida-
tion. OnlytheEXgrouphadhigherCPT-1activitythanSED
(Figure 4(a); P<0.05). EX and n3PUFA+EX had higher
citrate synthase activity followed by SED (Figure 4(e)), and
there were no diﬀerences among groups in β-HAD activity,
though a main eﬀect of treatment groups versus SED
approached signiﬁcance (Figure 4(f); P = 0.059). Rats in
the n3PUFA-SED and n3PUFA+EX groups had signiﬁcantly
higher total FAO (14CO2 + 14CA S M )a sc o m p a r e dt o
SED and EX rats (Figure 4(c)). This elevation in total
FAO was due to elevated incomplete fatty acid oxidation
as shown by higher ASM production (data not shown).
Further, in the presence of etomoxir, which inhibits CPT-
1 thereby ceasing the transport of long-chain fatty acids
to the mitochondria, n3PUFA-SED and n3PUFA+EX had
higher rates of FAO than the EX group but not the SED
group (Figure 4(d)). This suggests that the dietary intake
of n3PUFAs increases extramitochondrial total FAO in both
SED and EX conditions. In addition, EX was the only
group to have signiﬁcantly higher complete FAO (14CO2)a s
compared to SED, n3PUFA-SED, and n3PUFA+EX as shown
in Figure 4(b).
3.6. Hepatic Transcription Factors and Fatty Acid Synthesis
Pathway. PPARα mRNA expression was signiﬁcantly lower
in EX and n3PUFA+EX (Figure 5(a)). The expression of
PPARδ, a transcription factor associated with mitochondrial
biogenesis and fatty acid oxidation, was 3-fold higher in
EX as compared to SED, n3PUFA-SED, and n3PUFA+EX
(Figure 5(b)). However, there were no diﬀerences in protein
expression of PPARα or δ among groups as shown in Figures
5(c) and 5(d). The nuclear protein content of SREBP-1c did
not diﬀer among groups, although there was a trend toward
signiﬁcance (P = 0.09) as seen in Figure 6(a). There also
was a trend (P = 0.09) for a main eﬀect for treatment on
ACC protein content. However, the EX rats had signiﬁcantly
lower FAS protein content (P = 0.02) as compared to SED,
n3PUFA-SED, and n3PUFA+EX. There were no diﬀerences
in PPARγ protein content among groups (representative
western blot shown in Figure 6(f)). EX rats also had the
lowest protein content of SCD-1 as compared to the other
groups (Figure 6(d)). SCD-1 desaturase index was lowest
in EX and highest in n3PUFA-SED rats as estimated by
product (16:1) to substrate (16:0) ratio for the enzyme
(Figure 6(e)).
4. Discussion
The primary objectives of the current study were to deter-
mine if exercise and n3PUFA supplementation, alone or in
combination, could eﬀectively treat hepatic steatosis in obese
OLETF rats and to determine if these treatment strategies
were associated with changes in insulin sensitivity, hepatic
mitochondrial FAO, or markers of hepatic lipogenesis. The
major ﬁndings include the following: (1) exercise treat-
ment reversed preexisting hepatic steatosis in association
with elevated hepatic complete FAO and CPT-1 activity,
improved systemic insulin sensitivity, and decreased markers
of hepatic lipogenesis; (2) n3PUFAs supplemented at 3%
of diet increased TAG accumulation in the liver and, when
combined with exercise n3PUFAs, did not lead to additive
health beneﬁts, but instead partially blunted the beneﬁcial
eﬀects of exercise to reduce hepatic TAG accumulation and
improve insulin sensitivity.
EX was the only treatment that reversed liver TAG
content below the pretreatment levels measured in 13-week-
old sedentary OLETF animals. It is likely that EX lowered
hepatic steatosis in part by slowing gains in body weight and
fat mass that normally occur in SED conditions. However,
the data also supports the notion that EX induced a hepatic
metabolic phenotype that played a role in reducing steatosis
as well. Evidence suggests that EX increased both the mito-
chondrial entry rate (higher CPT-1 activity (Figure 4(a))
and complete catabolism of long-chain fatty acids (increased
complete palmitate oxidation to CO2 (Figure 4(b)). The
increaseincompleteoxidationislikelyduetoamoreeﬃcient
coupling of increased β-oxidation and TCA cycle ﬂux. EX
alsoloweredextramitochondrialhepaticFAO(oxidationthat
occurs in the presence of CPT-1 inhibition with etomoxir
(Figure 4(d)). Our assumption is that extramitochondrial
oxidation is primarily driven by peroxisomes, organelles that
break down longer chain fatty acids so that they can then
be oxidized in the mitochondria. Peroxisomal activity has
previously been shown to be higher in the SED OLETF [30]
andwhennotpairedwithincreasedmitochondrialFAO[31–
33] could lead to the accumulation of fatty acid metabolites
and oxidative stress.
Livers were examined 5 hours after the last exercise bout,
opening the possibility that the exercise-induced adaptations
were primarily due to the last bout of exercise rather than
a result of chronic training. In a previous study from our
group, OLETF rats exercised on voluntary running wheels
for XX weeks before we locked the wheels to stop exercise
[12]. We then examined hepatic responses 5 hours, 53 hours
(2 days), and 173 hours (7 days) after the last exercise bout
allowing us to determine if 2 or 7 days of inactivity led to
diﬀerent outcomes than the group studied 5 hours after the
last bout. In addition, all 3 groups were also compared to
OLETFs who were never provided access to running wheels.
Most measures of mitochondrial content were unchanged
by 7 days of inactivity and were still higher than sedentaryJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
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Figure 3: Insulin sensitivity. Peripheral insulin sensitivity was assessed by intraperitoneal glucose tolerance tests represented as changes in
blood glucose over time (a), glucose area under the curve (AUC) (b), and insulin AUC (c). Values are means ± SE (n = 8). ∗EX is diﬀerent
from other groups, #n3PUFA+EX is diﬀerent from SED, $n3PUFA+EX is diﬀerent from n3PUFA-SED (P<0.05). Values with diﬀerent letter
superscripts are signiﬁcantly diﬀerent from each other (P<0.05).
livers, while markers of de novo lipogenesis (FAS and ACC
protein content and malonyl CoA) increased signiﬁcantly 2
and 7 days after the cessation of exercise. Hepatic TAG did
not increase signiﬁcantly 7 days after the cessation of exercise
and remained signiﬁcantly lower than the content measured
in sedentary rats. Thus, these data suggest that some hepatic
adaptationstoEXtreatmentaresustainedandduetochronic
training while others are dependent on the eﬀects of the last
bout.
Peripheral insulin resistance is strongly associated with
hepatic steatosis. Importantly, high levels of circulating
insulin activate SREBP-1c, a master regulator of lipid
synthesis. Here we report that EX had the most powerful
eﬀects on reducing glucose and insulin levels during the
IPGTT.Similartoourpreviousreportsofexercisepreventing
the development of insulin resistance in the OLETF model
[9, 12, 34], here we demonstrate that exercise also can
be used as a treatment to improve insulin sensitivity. We
also originally hypothesized that EX or dietary n3PUFAs
would reduce the mature form of SREBP-1c and would
play a key role in downregulating fatty acid synthesis in
the liver [16, 18, 35–37]. In addition, we hypothesized
that n3PUFAs would activate PPARα and δ,a sn 3 P U F A s
are known to be natural ligands and potent activators of
PPARs. Surprisingly, the mature, nuclear form of SREBP-
1c was not signiﬁcantly altered by any of the treatments
and n3PUFAs did not potently increase expression or
protein content of PPARs. However, although there were
no changes in SREBP-1c, protein content of FAS and SCD-
1, its downstream targets, was dramatically reduced with
EX. It is possible that the trend for lowering of nuclear
SREBP-1c was enough to lower FAS and SCD-1 or that EX8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 4: Hepatic fatty acid oxidation. Carnitine palmitoyl transferase (CPT)-1 activity (a), hepatic complete fatty acid oxidation (14CO2)
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the presence of etomoxir (d), citrate synthase activity (e), and β-HAD activity (f). Values with diﬀerent letter superscripts are signiﬁcantly
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Figure 5: PPAR expression. mRNA expression of PPARα (a) and PPARδ (b) and protein content of PPARα (c) and PPARδ (d). Values with
diﬀerent letter superscripts are signiﬁcantly diﬀerent from each other (P<0.05).
lowered these factors through other pathways. Through the
conversion of saturated fatty acids to monounsaturated fatty
acids, hepatic SCD-1 contributes to abnormal partitioning
of fatty acids by reducing FAO and increasing fatty acid
synthesis. EX signiﬁcantly suppressed SCD-1 expression and
activity, resulting in lower desaturation of the fatty acid
within hepatic TAG which is consistent with our previous
results. In contrast, n3PUFA did not impact SCD-1 content
and slightly increased activity as shown by the desaturase
index. FAS is also a critical step in the conversion of
carbohydrates to fatty acids through de novo lipogenesis. All
told, EX lowered markers of hepatic lipogenesis, but because
this occurred without a clear lowering of nuclear SREBP-1c
content, we are unsure these changes are directly linked to
reduced circulating insulin and improved systemic insulin
sensitivity.
Contrary to our original hypothesis and the results of
others, we found that n3PUFA supplementation in SED
OLETFs led to increased TAG accumulation in the liver
[16, 19, 20, 35, 38]. Although our results are conﬂicting
with a large majority of the literature, it should be noted
that the majority of ﬁsh oil/n3PUFA research conducted
in animals uses excessive amounts (6–60% of energy) that
are not likely physiologically relevant [16, 35–41]. Here we
used a diet consisting of 3% of total energy from ﬁsh oil
which is a concentration that can safely be consumed by
humans [42]. Consequently, it may require higher dosages
of n3PUFAs to yield the health beneﬁts found by others in
their rodent models. In addition, we started treatment at 13
weeks of age, an age where OLETFs several obesity-induced
comorbidities such as NAFLD, systemic insulin resistance,
and increased adiposity are present which may explain the10 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 6: Lipogenic markers. Protein content of nuclear SREBP-1c (a), ACC (b), FAS (c), SCD-1, and PPARγ (d). Representative blots are
shown in (f) for each of the target proteins. Desaturase index is indicative of SCD-1 desaturase activity and is shown by the ratio of 16:1 to
16:0 (e). Values with diﬀerent letter superscripts are signiﬁcantly diﬀerent from each other (P<0.05).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 11
diﬀerences seen between prevention and treatment with
n3PUFAs. An alternative and more probable explanation is
that dietary consumption of “healthy” fatty acids cannot
likely overcome a hyperphagic, chronic state of positive
energy balance and daily weight gain in sedentary rats.
Excess energy intake, regardless of the source, will likely
result in increased adiposity and ectopic fat storage if not
matched with increased energy expenditure. Rather, either
loweringtotalenergyintakeorincreasingenergyexpenditure
is likely needed to eﬀectively treat hepatic steatosis. Future
experiments are needed to determine if n3PUFA intake
w o u l db em o r ee ﬀective in reducing steatosis in animals in
which the rate of weight gain is reduced by limiting caloric
consumption. There are also human clinical implications
to these ﬁndings. If patients are in a constant positive
energy balance and continuing to gain weight, it is unlikely
that increasing dietary n3PUFA would lower hepatic fat
content.
In conclusion, our study documents the detrimental
eﬀects of overeating while remaining sedentary on adiposity,
insulin sensitivity, hepatic mitochondrial function, and
hepatic steatosis. Moreover, these adverse events occurred
regardless of supplementing n3PUFAs in the diet. However,
daily exercise eﬀectively treats hepatic steatosis in obese
OLETF rats in part by increasing hepatic mitochondrial
function and complete fatty acid oxidation, decreasing
activation of the lipid synthesis pathway, and improving
systemic insulin sensitivity. Furthermore, treatment with
n3PUFAs partially blunted the beneﬁcial eﬀects of exercise
in this hyperphagic animal model by unknown mecha-
nisms.
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